Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study
- 11 December 1999
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 354 (9195), 2036-2040
- https://doi.org/10.1016/s0140-6736(99)06092-4
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- IntroductionAmerican Journal of Obstetrics and Gynecology, 1998
- Molecular Biology and Pathophysiology of APC Resistance: Current Insights and Clinical ImplicationsSeminars in Thrombosis and Hemostasis, 1998
- Oral contraceptives and venous thromboembolismThe Lancet, 1997
- End of the line for “third-generation-pill” controversy?The Lancet, 1997
- Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptivesBritish Journal of Haematology, 1997
- Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individualsBlood Coagulation & Fibrinolysis, 1997
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic diseaseThe Lancet, 1995
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Oral Contraceptives and Cardiovascular DiseaseThe New England Journal of Medicine, 1981